Evidence map›Paper›PMID 37014919›Full record

ArticlePLoS neglected tropical diseases2023

Schistosomiasis screening in non-endemic countries from a cost perspective: Knowledge gaps and research priorities. The case of African long-term residents in a Metropolitan Area, Spain.

Sílvia Roure, Francesc López, Irene Oliva, Olga Pérez-Quílez, Oriol March, Anna Chamorro, Elena Abad, Israel López Muñoz, Amaia Castillo, Laura Soldevila and 16 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.1field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 6 institutions in 1 country.

Sílvia RoureInternational Health Program (PROSICS), Direcció Territorial de Malalties Infeccioses Metropolitana Nord, Institut Català de la Salut, Badalona, Spain.
Francesc LópezCentre de Recerca en Economia de la Salut (CRES), Universitat Pompeu Fabra, Barcelona, Spain.
Irene OlivaGrup de Recerca en Innovació, Economia de la Salut i Transformació Digital (Institut de Recerca Germans Trias i Pujol-IGTP), Badalona, Spain.
Olga Pérez-QuílezInternational Health Program (PROSICS), Direcció Territorial de Malalties Infeccioses Metropolitana Nord, Institut Català de la Salut, Badalona, Spain.
Oriol MarchGrup de Recerca en Innovació, Economia de la Salut i Transformació Digital (Institut de Recerca Germans Trias i Pujol-IGTP), Badalona, Spain.
Anna ChamorroFight and Infectious Diseases Foundation, Badalona, Spain.
Elena AbadFight and Infectious Diseases Foundation, Badalona, Spain.
Israel López MuñozInternational Health Program (PROSICS), Direcció Territorial de Malalties Infeccioses Metropolitana Nord, Institut Català de la Salut, Badalona, Spain.
Amaia CastilloInternational Health Program (PROSICS), Direcció Territorial de Malalties Infeccioses Metropolitana Nord, Institut Català de la Salut, Badalona, Spain.
Laura SoldevilaInternational Health Program (PROSICS), Direcció Territorial de Malalties Infeccioses Metropolitana Nord, Institut Català de la Salut, Badalona, Spain.
Lluís ValerioInternational Health Program (PROSICS), Direcció Territorial de Malalties Infeccioses Metropolitana Nord, Institut Català de la Salut, Badalona, Spain.
Manolo LozanoNeurology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Helena MasnouGastroenterology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Mario OliveiraUrology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Laura CañasNephrology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Mireia GibratPrimary Health Care Unit Canovelles, North Metropolitan Health Region from Barcelona, Institut Català de la Salut, Granollers, Spain.
Marta ChuecosPrimary Health Care Unit Mataró-3 (Rocafonda-Palau), North Metropolitan Health Region from Barcelona, Institut Català de la Salut, Badalona, Spain.
Juan José MonteroPrimary Health Care Unit Mataró-3 (Rocafonda-Palau), North Metropolitan Health Region from Barcelona, Institut Català de la Salut, Badalona, Spain.
Karen ColmenaresUnitat de Suport Assistencial i Avaluació (USUAiA), Direcció d'Atenció Primària Metropolitana Nord, Institut Català de la Salut, Sabadell, Spain.
Gemma FalgueraNorth Metropolitan Primary Care Directorate, Instiut Català de la Salut, Sabadell, Spain.
Josep Maria BonetNorth Metropolitan Primary Care Directorate, Instiut Català de la Salut, Sabadell, Spain.
Mar IsnardNorth Metropolitan Primary Care Directorate, Instiut Català de la Salut, Sabadell, Spain.
Núria PratNorth Metropolitan Primary Care Directorate, Instiut Català de la Salut, Sabadell, Spain.
Oriol EstradaGrup de Recerca en Innovació, Economia de la Salut i Transformació Digital (Institut de Recerca Germans Trias i Pujol-IGTP), Badalona, Spain.
Bonaventura ClotetFight and Infectious Diseases Foundation, Badalona, Spain.
Xavier VallèsInternational Health Program (PROSICS), Direcció Territorial de Malalties Infeccioses Metropolitana Nord, Institut Català de la Salut, Badalona, Spain.ORCID 0000-0002-4445-1490
Institut Català de la Salut · ESHospital Universitari Germans Trias i Pujol · ESInstitut d'Investigació en Ciències de la Salut Germans Trias i Pujol · ESFundació Lluita contra les Infeccions · ESIrsiCaixa · ESUniversitat Pompeu Fabra · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImported schistosomiasis is an emerging issue in European countries as a result of growing global migration from schistosomiasis-endemic countries, mainly in sub-Saharan Africa. Undetected infection may lead to serious long-term complications with an associated high cost for public healthcare systems especially among long-term migrants.

objectiveTo evaluate from a health economics perspective the introduction of schistosomiasis screening programs in non-endemic countries with high prevalence of long-term migrants. METHODOLOGY: We calculated the costs associated with three approaches-presumptive treatment, test-and-treat and watchful waiting-under different scenarios of prevalence, treatment efficacy and the cost of care resulting from long-term morbidity. Costs were estimated for our study area, in which there are reported to reside 74,000 individuals who have been exposed to the infection. Additionally, we methodically reviewed the potential factors that could affect the cost/benefit ratio of a schistosomiasis screening program and need therefore to be ascertained.

resultsAssuming a 24% prevalence of schistosomiasis in the exposed population and 100% treatment efficacy, the estimated associated cost per infected person of a watchful waiting strategy would be €2,424, that of a presumptive treatment strategy would be €970 and that of a test-and-treat strategy would be €360. The difference in averted costs between test-and-treat and watchful waiting strategies ranges from nearly €60 million in scenarios of high prevalence and treatment efficacy, to a neutral costs ratio when these parameters are halved. However, there are important gaps in our understanding of issues such as the efficacy of treatment in infected long-term residents, the natural history of schistosomiasis in long-term migrants and the feasibility of screening programs.

conclusionOur results support the roll-out of a schistosomiasis screening program based on a test-and-treat strategy from a health economics perspective under the most likely projected scenarios, but important knowledge gaps should be addressed for a more accurate estimations among long-term migrants.

Indexed as

SchistosomiasisCost-Benefit AnalysisEuropeHumansPrevalenceResearchSpain

Identifiers

PMID37014919
PMCPMC10104311
OpenAlexW4362521403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.